Interleukin gains patent for sepsis gene:
This article was originally published in Clinica
Executive Summary
Interleukin Genetics has gained a US patent relating to a genetic marker that could lead to a DNA test for identifying patients who have a significantly increased risk of dying from sepsis. The Waltham, Massachusetts-based company has discovered that common variations in the human IL-1B gene are associated with a much higher risk of dying from the infection, which affects tens of thousands of people in the US annually.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.